Centoxin

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1992-2012
024619922012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
This paper examines the development and termination of nebacumab (Centoxin®), a human IgM monoclonal antibody (mAb) drug… (More)
Is this relevant?
2004
2004
Lyell's syndrome (LS) (toxic epidermal necrolysis) is also known as “scalded skin syndrome.” When caused by staphylococci, it has… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
1998
1998
This note describes the binding specificities of four lipid A monoclonal antibodies (MAbs) including Centoxin (HA-1A); these MAbs… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1998
1998
 
Is this relevant?
1996
1996
The uncertain fate of individual patients in intensive care results from the heterogeneity of case-mix, life threatening insults… (More)
  • figure 1
  • table 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1995
1995
Human IgM monoclonal antibody A6H4C5 was manufactured by Centocor (Malvern, PA) and used in clinical trials as HA-1A (Centoxin… (More)
Is this relevant?
1994
1994
The cytokines interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF alpha) have been… (More)
Is this relevant?
1994
1994
OBJECTIVE The in vivo neutralizing activities of an anti-lipopolysaccharide (LPS) antibody HA-1A (Centoxin [Centocor, Malvern, PA… (More)
Is this relevant?
Review
1993
Review
1993
Centoxin is one of a new group of immunotherapeutic agents manufactured from 'humanized' antibodies produced using monoclonal… (More)
Is this relevant?
1992
1992
Monoclonal antibodies have been shown to reduce morbidity and mortality in selected subsets of patients with Gram-negative sepsis… (More)
Is this relevant?